Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Brian Beardslee"'
Autor:
Harry Klein, Tali Mazor, Ethan Siegel, Pavel Trukhanov, Andrea Ovalle, Catherine Del Vecchio Fitz, Zachary Zwiesler, Priti Kumari, Bernd Van Der Veen, Eric Marriott, Jason Hansel, Joyce Yu, Adem Albayrak, Susan Barry, Rachel B. Keller, Laura E. MacConaill, Neal Lindeman, Bruce E. Johnson, Barrett J. Rollins, Khanh T. Do, Brian Beardslee, Geoffrey Shapiro, Suzanne Hector-Barry, John Methot, Lynette Sholl, James Lindsay, Michael J. Hassett, Ethan Cerami
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-9 (2022)
Abstract Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs to advance precision med
Externí odkaz:
https://doaj.org/article/0c617a60fa3f432c8f9c2b34b3ebd0b8
Autor:
Mary E. Larkin, Catherine A. Griffith, Donna J. Perry, Marielle T Mugford, Elizabeth Witte, Wen Ni, Kerry Milaszewski, Sabune J. Winkler, Enrico Cagliero, Brian Beardslee, Joanna M Myerson
Publikováno v:
Nursing ethics. 26(1)
Background:Clinical investigation is a growing field employing increasing numbers of nurses. This has created a new specialty practice defined by aspects unique to nursing in a clinical research context: the objectives (to implement research protocol
Autor:
Matthew Volm, Coral Omene, Amy Tiersten, M Meyers, Samantha Davis, Brian Beardslee, Yelena Novik, S.C. Formenti, Robert J. Schneider, Sylvia Adams, Jasmeet Chadha Singh, Judith D. Goldberg, James L. Speyer, Julia Smith, Xin Li
Publikováno v:
Cancer Research. 72:P5-20
BACKGROUND: RAD001 is an oral mTOR inhibitor that has exhibited activity in breast cancer. Triple negative breast cancer cells are unable to repair double stranded DNA breaks and hence have sensitivity to platinum agents that cause interstrand cross-
Autor:
Amber Scotton, Brian Beardslee, Khanh T. Do, Geoffrey I. Shapiro, Sheelagh Frame, Solida Pruitt-Thompson, Daniella Zheleva, Ketki Bhushan, Nicole G. Chau, David Blake, Andrew Wolanski, Judy H. Chiao, Faith Hassinger
Publikováno v:
Cancer Research. 78:CT037-CT037
Background: CYC065 is a potent and selective inhibitor of CDK2 and CDK9. CDK2 drives cell cycle transition and activates major DNA double-strand break repair pathways; CDK9 regulates transcription of genes through phosphorylation of RNAP II. This fir
Autor:
Solida Pruitt-Thompson, Geoffrey I. Shapiro, Leena Gandi, Bruce E. Johnson, Faith Hassinger, Geoffrey R. Oxnard, James M. Cleary, Alona Muzikansky, Ketki Bhushan, Kwok-Kin Wong, Nicole G. Chau, Elizabeth Downey, John Hilton, Andrew Wolanski, Jeffrey G. Supko, Adrienne Anderson, Joseph W. Gibson, Nora Feeney, Suzanne M. Barry, Cloud P. Paweletz, Pasi A. Jänne, Brian Beardslee
Publikováno v:
Cancer Research. 77:CT046-CT046
Background: Both MEK and CDK4/6 have been investigated as therapeutic targets in preclinical models of RAS mutant solid tumors. Multiple mechanisms contribute to synergism including the development of MAP kinase-dependence in RAS mutant cells exposed
Autor:
Khanh T. Do, Suzanne M. Barry, James M. Cleary, Bose Kochupurakkal, Dongpo Cai, Sara M. Tolaney, Andrew Wolanski, Solida Pruitt-Thompson, John Hilton, Jeffrey G. Supko, Elizabeth Downey, Alan D. D'Andrea, Richard Piekarz, Joseph Geradts, Geoffrey I. Shapiro, L. Austin Doyle, Alona Muzikansky, Ketki Bhushan, Christine Unitt, Brian Beardslee, Faith Hassinger
Publikováno v:
Cancer Research. 77:CT047-CT047
Background: Although PARP inhibition is effective against HR repair-deficient cancers, efficacy is limited by HR proficiency, whether present de novo or as a result of acquired resistance, prompting HR disrupting strategies to sensitize tumor cells.
Autor:
Sylvia Adams, Brian Beardslee, Yelena Novik, Coral Omene, Julia Smith, James L. Speyer, Judith D. Goldberg, Jasmeet Chadha Singh, Xiaochun Li, Silvia C. Formenti, M Meyers, Amy Tiersten, Samantha Davis, Matthew Volm, Robert J. Schneider
Publikováno v:
Journal of Clinical Oncology. 30:108-108
108 Background: Triple-negative breast cancer cells are unable to repair double stranded DNA breaks and have sensitivity to platinum agents. Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in breast c
Autor:
Silvia C. Formenti, Coral Omene, Sylvia Adams, Samantha Davis, Matthew Volm, James L. Speyer, Franco M. Muggia, Brian Beardslee, Yelena Novik, Jasmeet Chadha Singh, Amy Tiersten, Robert J. Schneider, M Meyers, Stacy Stein, Julia Smith
Publikováno v:
Journal of Clinical Oncology. 30:e11529-e11529
e11529 Background: Triple negative breast cancer cells are unable to repair double stranded DNA breaks and hence have sensitivity to platinum agents. Rapamycin acts synergistically with platinum agents to induce apoptosis and inhibit proliferation in